George Follows

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ...

Fase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kin...

Selinexor bij recidief/refractair DLBCL: SADAL fase II

Acalabrutinib met of zonder obinutuzumab versus chlorambucil-obinutuzumab bij onbehandelde CLL: ELEVATE-TN fase III